Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background and Purpose Standard operating procedures (SOP) incorporating plasma levels of rivaroxaban might be helpful in selecting patients with acute ischemic stroke taking rivaroxaban suitable for IVthrombolysis(IVT) or endovascular treatment (EVT). Methods This was a single-center explorative analysis using data from the Novel-Oral-Anticoagulants-in-Stroke-Patients-registry (clinicaltrials.gov:NCT02353585) including acute stroke patients taking rivaroxaban(September 2012 to November 2016). The SOP included recommendation, consideration, and avoidance of IVT if rivaroxaban plasma levels were <20 ng/mL, 20‒100 ng/mL, and >100 ng/mL, respectively, measured with a calibrated anti-factor Xa assay. Patients with intracranial artery occlusion were recommended IVT+EVT or EVT alone if plasma levels were ≤100 ng/mL or >100 ng/mL, respectively. We evaluated the frequency of IVT/EVT, door-to-needle-time (DNT), and symptomatic intracranial or major extracranial hemorrhage. Results Among 114 acute stroke patients taking rivaroxaban, 68 were otherwise eligible for IVT/EVT of whom 63 had plasma levels measured (median age 81 years, median baseline National Institutes of Health Stroke Scale 6). Median rivaroxaban plasma level was 96 ng/mL (inter quartile range [IQR] 18‒259 ng/mL) and time since last intake 11 hours (IQR 4.5‒18.5 hours). Twenty-two patients (35%) received IVT/EVT (IVT n=15, IVT+EVT n=3, EVT n=4) based on SOP. Median DNT was 37 (IQR 30‒60) minutes. None of the 31 patients with plasma levels >100ng/mL received IVT. Among 14 patients with plasma levels ≤100 ng/mL, the main reason to withhold IVT was minor stroke (n=10). No symptomatic intracranial or major extracranial bleeding occurred after treatment. Conclusions Determination of rivaroxaban plasma levels enabled IVT or EVT in one-third of patients taking rivaroxaban who would otherwise be ineligible for acute treatment. The absence of major bleeding in our pilot series justifies future studies of this approach.
Abstract
Background and Purpose Standard operating procedures (SOP) incorporating plasma levels of rivaroxaban might be helpful in selecting patients with acute ischemic stroke taking rivaroxaban suitable for IVthrombolysis(IVT) or endovascular treatment (EVT). Methods This was a single-center explorative analysis using data from the Novel-Oral-Anticoagulants-in-Stroke-Patients-registry (clinicaltrials.gov:NCT02353585) including acute stroke patients taking rivaroxaban(September 2012 to November 2016). The SOP included recommendation, consideration, and avoidance of IVT if rivaroxaban plasma levels were <20 ng/mL, 20‒100 ng/mL, and >100 ng/mL, respectively, measured with a calibrated anti-factor Xa assay. Patients with intracranial artery occlusion were recommended IVT+EVT or EVT alone if plasma levels were ≤100 ng/mL or >100 ng/mL, respectively. We evaluated the frequency of IVT/EVT, door-to-needle-time (DNT), and symptomatic intracranial or major extracranial hemorrhage. Results Among 114 acute stroke patients taking rivaroxaban, 68 were otherwise eligible for IVT/EVT of whom 63 had plasma levels measured (median age 81 years, median baseline National Institutes of Health Stroke Scale 6). Median rivaroxaban plasma level was 96 ng/mL (inter quartile range [IQR] 18‒259 ng/mL) and time since last intake 11 hours (IQR 4.5‒18.5 hours). Twenty-two patients (35%) received IVT/EVT (IVT n=15, IVT+EVT n=3, EVT n=4) based on SOP. Median DNT was 37 (IQR 30‒60) minutes. None of the 31 patients with plasma levels >100ng/mL received IVT. Among 14 patients with plasma levels ≤100 ng/mL, the main reason to withhold IVT was minor stroke (n=10). No symptomatic intracranial or major extracranial bleeding occurred after treatment. Conclusions Determination of rivaroxaban plasma levels enabled IVT or EVT in one-third of patients taking rivaroxaban who would otherwise be ineligible for acute treatment. The absence of major bleeding in our pilot series justifies future studies of this approach.
참고문헌 (36)
- Hacke W, "Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke", N Engl J Med, 359, pp.1317~1329 (2008)
- Hacke W, "Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators", Lancet, 352, pp.1245~1251 (1998)
- ): a randomised controlled trial, "Lancet", 2012, 2352~2363
- Wahlgren N, "Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study", Lancet, 369, pp.275~282 (2007)
- Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
- Hankey GJ, "Management of acute stroke in patients taking novel oral anticoagulants", Int J Stroke, 9, pp.627~632 (2014)
- Mazya MV, "Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin", Ann Neurol, 74, pp.266~274 (2013)
- Xian Y, "Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator", JAMA, 307, pp.2600~2608 (2012)
- Nogueira RG, "Safety and efficacy of endovascular thrombectomy in patients with abnormal hemostasis: pooled analysis of the MERCI and multi MERCI trials", Stroke, 40, pp.516~522 (2009)
- De Marchis GM, "Intracranial hemorrhage, outcome, and mortality after intra-arterial therapy for acute ischemic stroke in patients under oral anticoagulants", Stroke, 42, pp.3061~3066 (2011)
- Harenberg J, "Measurement of the new anticoagulants", Thromb Res, 129(Suppl 1), pp.S106~S113 (2012)
- Purrucker JC, "Coagulation testing in acute ischemic stroke patients taking non-vitamin K antagonist oral anticoagulants", Stroke, 48, pp.152~158 (2017)
- Cuker A, "Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants", J Am Coll Cardiol, 64, pp.1128~1139 (2014)
- Seiffge DJ, "Feasibility of rapid measurement of rivaroxaban plasma levels in patients with acute stroke", J Thromb Thrombolysis, 43, pp.112~116 (2017)
- Seiffge DJ, "Intravenous thrombolysis in stroke patients receiving rivaroxaban", Eur J Neurol, 21, pp.e3~e4 (2014)
- Ringelstein EB, "European Stroke Organisation recommendations to establish a stroke unit and stroke center", Stroke, 44, pp.828~840 (2013)
- Seiffge DJ, "Recanalization therapies in acute ischemic stroke patients:impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome", Circulation, 132, pp.1261~1269 (2015)
- Demaerschalk BM, "Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association", American Stroke Association, 2016, pp.47, 581~641
- Jauch EC, "Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2013, pp.44, 870~947
- Lyden P, "Improved reliability of the NIH stroke scale using video training. NINDS TPA Stroke Study Group", Stroke, 25, pp.2220~2226 (1994)
- Levey AS, "A new equation to estimate glomerular filtration rate", Ann Intern Med, 150, pp.604~612 (2009)
- Gensicke H, "IV thrombolysis and renal function", Neurology, 81, pp.1780~1788 (2013)
- Gensicke H, "Long-term outcome in stroke patients treated with IV thrombolysis", Neurology, 80, pp.919~925 (2013)
- Scheitz JF, "Dose-related effects of statins on symptomatic intracerebral hemorrhage and outcome after thrombolysis for ischemic stroke", Stroke, 45, pp.509~514 (2014)
- Hacke W, "Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)", JAMA, 274, pp.1017~1025 (1995)
- National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, "Tissue plasminogen activator for acute ischemic stroke", N Engl J Med, 333, pp.1581~1587 (1995)
- Dennis M, "Determining the modified rankin score after stroke by postal and telephone questionnaires", Stroke, 43, pp.851~853 (2012)
- Powers WJ, "2015 American Heart Association", American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association, Stroke, pp.2015, 46[DOI]
- Mueck W, "Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention", Clin Pharmacokinet, 50, pp.675~686 (2011)
- Steiner T, "Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban", Clin Res Cardiol, 102, pp.399~412 (2013)
- Barber PA, "Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta stroke programme early CT score", Lancet, 355, pp.1670~1674 (2000)
- Mueck W, "Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement", Thromb Haemost, 100, pp.453~461 (2008)
- Meretoja A, "Off-label thrombolysis is not associated with poor outcome in patients with stroke", Stroke, 41, pp.1450~1458 (2010)
- Kepplinger J, "Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol", J Thromb Thrombolysis, 41, pp.293~300 (2016)
- Xian Y, "Use of intravenous recombinant tissue plasminogen activator in patients with acute ischemic stroke who take non-vitamin K antagonist oral anticoagulants before stroke", Circulation, 135, pp.1024~1035 (2017)
- Ebner M, "Point-of-care testing of coagulation in patients treated with non-vitamin K antagonist oral anticoagulants", Stroke, 46, pp.2741~2747 (2015)